TW202144381A - 用於炎症之化合物 - Google Patents
用於炎症之化合物 Download PDFInfo
- Publication number
- TW202144381A TW202144381A TW110107292A TW110107292A TW202144381A TW 202144381 A TW202144381 A TW 202144381A TW 110107292 A TW110107292 A TW 110107292A TW 110107292 A TW110107292 A TW 110107292A TW 202144381 A TW202144381 A TW 202144381A
- Authority
- TW
- Taiwan
- Prior art keywords
- substituted
- unsubstituted
- compound
- day
- virus
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382152.5 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382192.1 | 2020-03-13 | ||
| EP20382266.3 | 2020-04-02 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382339.8 | 2020-04-27 | ||
| EP20382815.7 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP20382816.5 | 2020-09-16 | ||
| EP20382815 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| EP21382059.0 | 2021-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202144381A true TW202144381A (zh) | 2021-12-01 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110107292A TW202144381A (zh) | 2020-03-02 | 2021-03-02 | 用於炎症之化合物 |
| TW110107293A TWI908772B (zh) | 2020-03-02 | 2021-03-02 | 用於病毒感染之化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110107293A TWI908772B (zh) | 2020-03-02 | 2021-03-02 | 用於病毒感染之化合物 |
Country Status (17)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4114436A1 (en) * | 2020-03-02 | 2023-01-11 | Pharma Mar S.A. | Compounds for use in the treatment of coronavirus infection |
| CN115666616A (zh) | 2020-03-02 | 2023-01-31 | 法马马有限公司 | 用于病毒感染的化合物 |
| IL296067A (en) * | 2020-03-02 | 2022-11-01 | Pharma Mar Sa | Pld for use in combination in the treatment of coronavirus |
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4493796A (en) | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US20030148933A1 (en) * | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| BR9909668A (pt) * | 1998-04-14 | 2000-12-19 | Jomaa Hassan | Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções |
| ES2272462T3 (es) | 2000-04-07 | 2007-05-01 | The Trustees Of The University Of Pennsylvania | Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso. |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| JP4623931B2 (ja) * | 2000-12-07 | 2011-02-02 | エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ | 炎症性疾患の治療用組成物 |
| US20070148192A1 (en) * | 2003-02-21 | 2007-06-28 | Laddha Ritu N | Stable ophthalmic composition |
| AU2004224418A1 (en) | 2003-03-21 | 2004-10-07 | Madeleine M. Joullie | Tamandarin analogs and fragments thereof and methods of making and using |
| HUE028055T2 (en) * | 2006-02-28 | 2016-11-28 | Pharma Mar Sa | Improved treatment of myeloma multiplex |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| JP5814933B2 (ja) * | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
| US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
| GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
| JP2017526728A (ja) * | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| US11771739B2 (en) * | 2017-06-16 | 2023-10-03 | Vanderbilt University | Methods and compositions for treating microbial inflammation |
| CN115666616A (zh) * | 2020-03-02 | 2023-01-31 | 法马马有限公司 | 用于病毒感染的化合物 |
-
2021
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 US US17/908,533 patent/US12630589B2/en active Active
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 UY UY0001039110A patent/UY39110A/es not_active Application Discontinuation
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
- 2021-03-02 PY PY202102117301A patent/PY2117301A/es unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es not_active Application Discontinuation
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 PY PY202102117308A patent/PY2117308A/es unknown
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
- 2021-03-02 TW TW110107293A patent/TWI908772B/zh active
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaddoura et al. | COVID-19 therapeutic options under investigation | |
| US20230295236A1 (en) | Compounds for use in inflammatory conditions | |
| Ahidjo et al. | Current perspective of antiviral strategies against COVID-19 | |
| KR20200131784A (ko) | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 | |
| Duan et al. | Current and future therapeutical approaches for COVID-19 | |
| Kalam et al. | Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies | |
| US20230158103A1 (en) | Pld for use in combination in the treatment of coronavirus | |
| WO2019141263A1 (zh) | 一种广谱抗肠道病毒的多肽及其应用 | |
| Kaur et al. | A comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel coronavirus syndrome–COVID-19 | |
| CN109414508A (zh) | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 | |
| EA050436B1 (ru) | Соединения для применения при воспалительных состояниях | |
| TW202144380A (zh) | 用於治療冠狀病毒感染之化合物 | |
| Gazina et al. | Viral targets of acylguanidines | |
| JP2007015926A (ja) | C型肝炎治療剤 | |
| Frediansyah et al. | Clinical Epidemiology and Global Health | |
| Singh et al. | Potential antiviral therapies for coronavirus disease 2019 (COVID-19) | |
| Fan et al. | Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities | |
| Jose et al. | Analyzing the Impermeable Structure and Myriad of Antiviral Therapies for SARS-CoV-2 | |
| Solomon | Investigating the role of cellular metabolism in human coronavirus replication | |
| EA050340B1 (ru) | Соединения для применения в лечении коронавирусной инфекции | |
| Ortiz et al. | New Drugs in Synthesis Research for Viral Diseases | |
| Modak | A review on the pathophysiology and potential drugs for Covid-19 | |
| CN118320091A (zh) | 胱天蛋白酶抑制剂的组合物及其使用方法 |